Log in to save to my catalogue

Clinical decisions by the molecular tumor board on comprehensive genomic profiling tests in Japan: A...

Clinical decisions by the molecular tumor board on comprehensive genomic profiling tests in Japan: A...

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_8a80aeda87b14dc480de839989bfda14

Clinical decisions by the molecular tumor board on comprehensive genomic profiling tests in Japan: A retrospective observational study

About this item

Full title

Clinical decisions by the molecular tumor board on comprehensive genomic profiling tests in Japan: A retrospective observational study

Publisher

United States: John Wiley & Sons, Inc

Journal title

Cancer medicine (Malden, MA), 2023-03, Vol.12 (5), p.6170-6181

Language

English

Formats

Publication information

Publisher

United States: John Wiley & Sons, Inc

More information

Scope and Contents

Contents

Background
A paradigm shift has occurred in cancer chemotherapy from tumor‐specific treatment with cytotoxic agents to personalized medicine with molecular‐targeted drugs. Thus, it is essential to identify genomic alterations and molecular features to recommend effective targeted molecular medicines regardless of the tumor site. Nevertheless, it...

Alternative Titles

Full title

Clinical decisions by the molecular tumor board on comprehensive genomic profiling tests in Japan: A retrospective observational study

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_doaj_primary_oai_doaj_org_article_8a80aeda87b14dc480de839989bfda14

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_8a80aeda87b14dc480de839989bfda14

Other Identifiers

ISSN

2045-7634

E-ISSN

2045-7634

DOI

10.1002/cam4.5349

How to access this item